# HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

> **NCT01266720** · PHASE1 · UNKNOWN · sponsor: **Fukushima Medical University** · enrollment: 6 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** VEGFR1, VEGFR2
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01266720
- **Lead sponsor:** Fukushima Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2010-03
- **Final completion:** 2012-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2010-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266720, "HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01266720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*